PHILADELPHIA — John Wherry, PhD, an associate professor of Microbiology in the Perelman School of Medicine at the University of Pennsylvania, and colleagues from Massachusetts General Hospital (MGH) are co-directing a $12 million grant to study immune responses in people who have been effectively cured of hepatitis C viral infection with new, high-potency antiviral drugs. This grant is part of the Cooperative Centers for Human Immunology program, administered by the National Institute of Allergy and Infectious Diseases.
"This is a unique medical opportunity to understand how immunity recovers after complete cure of a long-established chronic viral infection," says Wherry, who is also director of the Institute for Immunology at Penn.
Hepatitis C virus (HCV) infects 185 million people worldwide and is the leading need for liver transplantation. In the United States, HCV has a higher mortality rate than HIV. The annual healthcare costs associated with HCV exceed $9 billion, a number expected to increase as the epidemic matures and end-stage liver disease peaks over the next decade, says Wherry.
Because HCV is so persistent, it is a good model for studying chronic viral infection. Researchers think this persistence is because HCV, while inducing interferon expression, maintains its foothold in the body by globally suppressing the host’s two main types of immune response. Interferons are host proteins released in the presence of viruses, bacteria, parasites, and tumor cells that allow immune cells to communicate with each other to fight infection.
The mainstay of HCV treatment for the last two decades -- interferon-based drugs-- is ineffective in many patient subgroups and has significant side effects. The recent development of highly effective, direct-acting antivirals (DAA) against HCV promises to alter HCV treatment by offering a cure without interferon drugs. "However, it remains essential that we understand what type of immunity remains after this pharmacological eradication of HCV," says Wherry. Many HCV-infected people remain at risk for reinfection due to lifestyle and the DAAs are only partially effective in some patient subgroups, particularly those with past treatment with interferon drugs.
However, only patients with advanced disease typically receive DAAs, because current costs are very high for this new drug. The DAAs work in the majority of HCV patients receiving them, but a subset of them, about 10 to 40 percent, rebound with HCV after DAAs are stopped.
The investigators are working on the premise that a DAAmediated cure of chronic HCV infection will lead to partial resetting of some immune abnormalities, such as the restoration of functional T cell memory to the virus and improved responsiveness to the body’s own interferon. However, specific immunological defects may persist in some people who develop optimal immunity to HCV. Such results might suggest the need for HCV vaccination with, or following, DAA therapy, a topic the team is examining, notes Wherry.
The research being performed at Penn on this grant will focus on restoration of functional T cell memory and the epigenetic and transcriptional program of “exhausted” or dysfunctional T cells following HCV cure.
These studies will be performed in collaboration with researchers at MGH and Dana Farber Institute. The grant will also examine restoration of the effectiveness of the interferon system following an HCV cure (MGH), assess possible changes in the virus (Ragon Institute) and assess the impact of HCV vaccination as a complement to DAA-mediated cure of HCV (Oxford University, United Kingdom).
Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $4.3 billion enterprise.
The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 17 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $392 million awarded in the 2013 fiscal year.
The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania -- recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report; Penn Presbyterian Medical Center; Chester County Hospital; Penn Wissahickon Hospice; and Pennsylvania Hospital -- the nation's first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Chestnut Hill Hospital and Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2013, Penn Medicine provided $814 million to benefit our community.
Department of Communications
For Patients and the General Public: